Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sakeer Hussain (NPI 1952423071)

Field	Value
Entity Type	Individual
Organization	Sakeer Hussain
Address	1 Edmundson Pl
City	Council Bluffs
State	IA
ZIP	51503
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 6, 2007

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

Scale and payer mix: This provider reports $1.9M in lifetime Medicare revenue and has no Medicaid billing on file, so their publicly visible reimbursement footprint is effectively single‑payer Medicare rather than a dual‑payer mix. That concentration means analyses of utilization and contracting should treat Medicare as the dominant and near‑exclusive source of claims data for this clinician.

Revenue concentration: Three codes—J9271, J0897, and Q5122—account for a very large share of Medicare receipts; the precomputed top‑3 share is 78.9%. In raw terms J9271 alone accounts for $1.1M (62.2% of Medicare revenue), with J0897 at $169.6K (9.5%) and Q5122 at $127.8K (7.1%), signaling heavy dependence on a small set of drug administration codes.

Service‑line implications: The code mix is characteristic of an outpatient hematology/oncology infusion practice focused on systemic cancer therapy and supportive oncology care—high‑value immunotherapy (J9271, pembrolizumab), bone‑modifying therapy (J0897, denosumab), and growth‑factor support via a pegfilgrastim biosimilar (Q5122). Substantial chemotherapy administration codes (96413, 96365, 96417, 96415) and E/M codes for follow‑up visits (99213, 99214) further indicate integrated on‑site infusion and clinic visit workflows.

Competitive standing — pembrolizumab (J9271): Although J9271 drives the majority of this provider’s Medicare revenue ($1.1M, 62.2%), the provider ranks #207 of 1841 nationally (89th percentile) for this code and is described as having a typical, unremarkable volume relative to peers. In short, pembrolizumab is the single largest revenue driver here but the provider is not an extreme national outlier in market share for that drug.

Competitive standing — pegfilgrastim biosimilar (Q5122) and denosumab (J0897): Use of Q5122 is notably concentrated compared with peers—Q5122 ranks #8 of 239 nationally (97th percentile) and is flagged as notably above typical national volume—while J0897 ranks #1268 of 10057 (87th percentile) and is described as typical. This combination suggests the practice has an outsized role in administering biosimilar pegfilgrastim relative to other providers, even as its denosumab and pembrolizumab volumes sit within expected ranges for oncology clinicians.

Operational profile from visit and infusion codes: High counts and above‑typical percentiles for E/M and infusion add‑ons (e.g., 99214: 629 claims/$56K, 3.1% of revenue; 99213: 722 claims/$42.6K, 2.4%; 96413: 588 claims/$54.1K, 3.0%; 96367: 811 claims/$17K, 1.0%) indicate a steady stream of follow‑up visits coupled with frequent on‑site chemotherapy/infusion activity. Several of these codes are labelled “notably above typical” in percentile terms (96413, 96367, 99213), supporting an interpretation of regular, clinic‑based infusion throughput and follow‑up management of oncology patients.

Tenure and continuity: The provider’s NPI was enumerated on 2007-04-06 (~19 years ago), indicating long‑standing Medicare enrollment and an established presence in the market; longevity supports stable historical billing patterns for longitudinal benchmarking. Analysts should interpret current utilization in the context of nearly two decades of enrollment rather than a recent market entrant.

Concentration sensitivity and contracting implications: With $1.1M of $1.9M Medicare revenue tied to a single drug code (J9271) and the top three codes representing 78.9% of Medicare receipts, the provider’s revenue is highly concentrated in specific high‑cost oncology drugs and biosimilars. That concentration makes reimbursement and utilization policy changes for those agents, or shifts in referral patterns, likely to have an outsized impact on this clinician’s Medicare revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

52 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	25,900	$40	$1.1M
J0897	Injection, denosumab, 1 mg	9,420	$20	$169.6K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	1,400	$90	$127.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	630	$90	$56K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$90	$54.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	720	$60	$42.6K
J0185	Injection, aprepitant, 1 mg	29,250	$1	$29.3K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	4,680	$10	$28.1K
J1439	Injection, ferric carboxymaltose, 1 mg	25,500	$1	$25.5K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	810	$20	$17K

Showing 1–10 of 52

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 52 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Sakeer Hussain — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

52 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	30	17,200	$40	$902.3K
Q5122	1	10	530	$100	$75.4K
J0897	20	190	1,920	$20	$74.1K
J1439	10	10	41,250	$1	$39.7K
J0885	1	10	4,680	$10	$27.4K
96413	7	80	210	$90	$24K
M0010	1	10	210	$70	$15.2K
J0185	2	20	6,890	$1	$14.5K
99214	316	4,690	100	$70	$14.4K
99233	854	910	60	$90	$10.5K

Showing 1–10 of 52

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sakeer Hussain, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Crawford County Memorial Hospital	IA	Rural Health Clinic/Center	$0	$19.5M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Alegent Creighton Clinic	IA	Family Medicine Physician	$0	$9.6M
Shenandoah Medical Center	IA	Rural Health Clinic/Center	$0	$9.4M
Cass County Memorial Hospital	IA	Rural Health Clinic/Center	$0	$9.2M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0

Nearby Providers

Other providers in the same ZIP code as Sakeer Hussain, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Trivium Life Services	IA	Developmentally Disabled Services Day Training Agency	$0	$149.2M
Vocational Development Center Inc	IA	Developmentally Disabled Services Day Training Agency	$0	$59M
Rem Iowa Community Services, Inc	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$54.3M
Focus-family Options & Community Supports, Inc	IA	Developmentally Disabled Services Day Training Agency	$0	$41.2M
Council Bluffs Community School District	IA	Local Education Agency (LEA)	$0	$17.5M
Family Connections, Inc	IA	Case Management Agency	$0	$15.1M
Alegent Health Bergan Mercy Health System	IA	General Acute Care Hospital	$0	$13M
Jennie Edmundson Memorial Hospital	IA	General Acute Care Hospital	$0	$9.8M
City Of Council Bluffs	IA	Ambulance	$425.7K	$6.2M
Alegent Creighton Health	IA	Psychiatry Physician	$0	$5.8M

Sakeer Hussain — Billing Profile & Reimbursement Data

Sign up for Sakeer Hussain — Billing Profile & Reimbursement Data policy alerts

Sakeer Hussain — Billing Profile & Reimbursement Data

Sign up for Sakeer Hussain — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References